Trial · NCT03370913
Adverse events94
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 94
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | BMN 270 (Valoctocogene Roxaparvovec) | 119 | 134 | 385 |
| other | Aspartate aminotransferase increased | Investigations | BMN 270 (Valoctocogene Roxaparvovec) | 47 | 134 | 104 |
| other | Weight increased | Investigations | BMN 270 (Valoctocogene Roxaparvovec) | 22 | 134 | 36 |
| other | Blood creatine phosphokinase increased | Investigations | BMN 270 (Valoctocogene Roxaparvovec) | 17 | 134 | 22 |
| other | Blood lactate dehydrogenase increased | Investigations | BMN 270 (Valoctocogene Roxaparvovec) | 9 | 134 | 14 |
| other | Upper respiratory tract infection | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 33 | 134 | 45 |
| other | Nasopharyngitis | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 29 | 134 | 52 |
| other | Rhinitis | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 12 | 134 | 16 |
| other | Folliculitis | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 11 | 134 | 13 |
| other | Rash pustular | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 11 | 134 | 12 |
| other | Gastroenteritis | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 7 | 134 | 8 |
| other | Influenza | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 7 | 134 | 7 |
| other | Viral infection | Infections and infestations | BMN 270 (Valoctocogene Roxaparvovec) | 7 | 134 | 7 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 53 | 134 | 105 |
| other | Back pain | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 25 | 134 | 32 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 17 | 134 | 18 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 16 | 134 | 19 |
| other | Arthropathy | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 8 | 134 | 8 |
| other | Muscle spasms | Musculoskeletal and connective tissue disorders | BMN 270 (Valoctocogene Roxaparvovec) | 8 | 134 | 8 |
| other | Nausea | Gastrointestinal disorders | BMN 270 (Valoctocogene Roxaparvovec) | 51 | 134 | 79 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03370913/events